Key result
Endovascular treatment for TASC-II D aortoiliac disease resulted in a lower technical success rate than open repair, but showed no significant difference in major adverse limb events at 36 months.
Why the study?
Aortoiliac disease management remains debated, with shifting focus toward endovascular techniques even in complex cases.
Does endovascular treatment compared to open surgical repair improve outcomes in patients with symptomatic TASC-II D aortoiliac disease?
Cohort (n=89)
Yes
Does endovascular treatment compared to open surgical repair improve outcomes in patients with symptomatic TASC-II D aortoiliac disease?
Endovascular stenting for complex TASC-II D aortoiliac disease yields comparable mid-term cardiovascular and limb outcomes to open aortobifemoral bypass, despite a lower initial technical success rate.
Answers are grounded in this paper and cite their sources.
Both techniques show comparable long-term safety; leaves open optimal selection for TASC-II D lesions pending randomized trials.
Background: Aortoiliac disease management remains a subject of ongoing debate, with a shift in focus toward endovascular techniques, even in complex cases. This study aimed to evaluate and compare the safety and results of open surgery with endovascular surgery for treating TASC-II D aortoiliac lesions. Methods: From January 2013 to February 2021, the clinical data of 89 patients revascularized with symptomatic TASC ΙΙ D AID were analyzed in a prospective cohort study. The patients were divided into two groups: open repair (61 patients) and endovascular treatment (28 patients). Baseline characteristics, preoperative and postoperative imaging, operation procedure reports and follow-up were reviewed and analyzed. Kaplan-Meier survival analysis, multivariate Cox regression, and a Propensity Score Matching (PSM) analysis were used to evaluate the relevance between risk factors and surgical technique. Results: Open repair had a higher technical success rate (100% vs. 73.7%, p=0.01). 30-day major adverse cardiovascular (MACE) and limb (MALE) events showed no differences between both groups (PSM: 1 (4.8%) vs. 0, p=0.462 and 1 (4.8%) vs. 2 (13.3), p=0.235, respectively). Cox multivariable regression proportional hazard ratio showed no significant differences in terms of MALE between open and endovascular revascularization at 36 months (hazard ratio, HR 1.31 95% CI 0.56-3.06, p=0.54), even after PSM (HR 1.63 95% CI 0.58-4.55, p=0.35). Moreover, MACE and all-cause mortality also didn´t show a statistically significant difference between groups (HR 0.77 95% CI 0.22-2.64, p=0.67 and HR 0.97 95% CI 0.27-3.46, p=0.96). Conclusions: Open and endovascular techniques are safe and effective treatments for complex AIOD. It is expected to have a higher technical success rate with open repair; however, there are no significant differences in MACE or MALE between these two approaches.
No takes yet. Share an insight, caveat, or question.
Basílio-Martins et al. (2023) conducted a cohort in Symptomatic TASC-II D aortoiliac disease (n=89). Endovascular treatment (aortoiliac stenting) vs. Open surgical repair (aortobifemoral bypass) was evaluated on Major adverse limb events (MALE) at 36 months (post-PSM) (HR 1.63, 95% CI 0.58-4.55, p=0.35). Endovascular treatment for TASC-II D aortoiliac disease resulted in a lower technical success rate than open repair, but showed no significant difference in major adverse limb events at 36 months.
Synapse has enriched 10 related papers. Consider them for comparative context: